Option chain shows key data for GB Sciences's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for GB Sciences.

GB Sciences (OTC:GBLX) Stock, Option Chain

GB Sciences Inc is active in the healthcare sector. The company is engaged in developing and utilizing technologies in plant biology, cultivation, and extraction techniques combined with biotechnology, and plans to produce medical-grade cannabis, cannabis concentrates, and cannabinoid therapies. It seeks to be a technology and solution company that converts the cannabis plant into medicines, therapies, and treatments for a range of ailments. The company's intellectual property covers various medical conditions, from which five drug development programs are in the preclinical stage of drug development including its formulations for Parkinson's disease (PD), chronic pain, cytokine release syndrome, depression, and cardiovascular therapeutic programs.

thanksgivingcannabis

Cannabis

Health Care

GBLX

Discover 10 science-backed cannabis benefits for Thanksgiving, from reducing stress to boosting appetite, mood, and sleep quality.

Cannabis On Thanksgiving: 10 Science-Backed Benefits For A Happier Holiday

Photo: Courtesy Of CDC On Unsplash

News

Penny Stocks

Markets

Gb Sciences, Inc. (OTCQB: GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, co-published a study that demonstrates the potential of selected cannabinoids and terpenes to reduce inflammation.

Cannabis Terpenes Reduce Inflammation, Says Gb Sciences Study

General

Biopharmaceutical research and drug development company, Gb Sciences, Inc. (OTCQB: GBLX), co-published a study in the journal Frontiers in Pharmacology that demonstrates the efficacy of its proprietary cannabinoid-containing, minimum essential mixtures for the treatment of Parkinson&#39;s disease.

New Study Shows Promising Results In Treatment Of Parkinson&#39;s Disease With Cannabinoids

GB Sciences Inc

Biotech

Contracts

Press Releases

GB Sciences Signs Licensing Deal With EndoPure Life Sciences for 5% Gross Sales Royalty & Sponsorship of First-in-Human Trial for Their Cannabinoid-Based Parkinson's Drug

Comments

GB Sciences

GB Sciences (GBLX) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell